Article Text

Download PDFPDF
EP965 The impact of clinico-pathological features and surgery on relapse in women with borderline ovarian tumours: our experience
  1. I Rizzuto,
  2. HJ Jiang,
  3. R McDonnell,
  4. S Dohr,
  5. W MacNab and
  6. B Rufford
  1. Gynaecological Oncology Department, Ipswich Hospital NHS Trust, Ipswich, UK


Introduction/Background The current study was carried out to evaluate the oncological outcomes in patients with borderline ovarian tumours (BOT) according to type of surgery (conservative surgery versus radical surgery), stage at diagnosis and clinicopathological parameters.

Methodology We enrolled patients with BOT of any FIGO stage, whom were surgically treated from 2005 to 2013 at the Gynecological Oncology Department of the Ipswich hospital, UK. The prognostic effects of stage, clinico-pathological features (micropapillary lesions, invasive implants and bilateral tumors) and surgical variables were evaluated using univariate/multivariate analysis.

Results A total of 85 eligible patients were enrolled in the analysis. We had 42/85(49%) with serous, 35/85 (41%) with mucinous, 5/85(6%) with mixed mucinous-serous, 3/85 (4%) with endometroid histological subtypes. Among all the cohort of patients, 14/85 (16%) had recurrence within 5 years of follow-up. Multivariate analysis showed a significant association to relapse in the presence of micropapillary lesions and invasive implants at the histological report with RR 1.39 (95% CI 1.39–2.73) p -value < 0.001 and RR 4.44 (95% CI 2.26–8.69) p -value 0.002 respectively. FIGO stage RR 0.56 (95% CI 0.23–1.33) p -value 0.153, the presence of bilateral tumours RR 2.02 (95% CI 0.95–4.31) p -value 0.099 and conservative surgery RR 1.25 (95% CI 0.41–3.81) p -value 0.709 were not significantly associated to higher recurrence rate.

Conclusion We confirm that BOT patients with micropapillary lesions and invasive implants have high risk of recurrence. These data can support clinicians in tailoring the best surgical strategy in young patients with BOT and in counseling patient about their prognosis after the diagnosis.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.